Gaucher Type 3 Unfolds

Proper classification is crucial when managing Gaucher disease1 . However, shared symptomatology between Gaucher disease type 1 and type 3, along with lack of specific testing, make it difficult to distinguish subtypes, often leading to reclassification.^2-7

Consistent monitoring is key to proper classification of Gaucher disease type 3^1,2,8

Download our quick-learning tools to review the classic hallmark symptoms of Gaucher disease type 3 along with an in depth look at neurological manifestations

To Learn More

SANOFI, United Arab Emirates,

Level 3, One JLT, Jumeirah Lake Towers (JLT), DMCC, PO Box 53899, Dubai, UAE 
Tel.: +971 4 550 3600 | Fax: +971 4 5521050.
For further medical information, please contact: For UAE ✆ 800 MEDICAL Toll-Free Number.
For all Gulf countries ✆ +971 45 50 38 63 or email: medical-information.gulf@sanofi.com.
To report an adverse event or drug reaction, 
please contact us on: 24/ 7 Pharmacovigilance reporting number: +971 561747001 
e-mail: gulf.pharmacovigilance@sanofi.com

SANOFI, SAUDI ARABIA,
TAHLIA STREET,  NOJOUD CENTER, GATE C, 1ST FLOOR, P.O. BOX 9874, JEDDAH 21423, SAUDI ARABIA
For Medical Information: Please contact: +966126693318 
Email: ksa.medicalinformation@sanofi.com, Website: www.sanofi.com.sa
For Pharmacovigilance, Please contact: +966-54-428-4797, ksa_pharmacovigilance@sanofi.com
To report any product technical complaints, kindly contact quality.greatergulf@sanofi.com.
To report any side effect(s),Saudi Arabia: The National Pharmacovigilance Centre (NPC): SFDA Call Center: 19999, 
E-mail: npc.drug@sfda.gov.sa Website: https://ade.sfda.gov.sa